Therapeutic Drug Monitoring (TDM)

Infliximab and adalimumab are the most commonly used biologic drugs that target TNF-alpha in a range of different chronic inflammatory diseases such as Inflammatory Bowel Disease (IBD) or Rheumatoid Arthritis (RA). Therapeutic Drug Monitoring (TDM) encompasses measuring drug levels in patient’s blood and the occurrence of antibodies that block the drug (anti-drug antibodies or ADA). With the Quantum Blue® TDM assays, BÜHLMANN offers a menu of rapid tests for fast and reliable determination of biologic trough levels and anti-drug antibodies. The time to result of 15 minutes allows for quick decision making and optimization of patient’s treatment.

Adapted from Mitrev et al. 2017

Figure 1: Treatment algorithm adapted from Mitrev et al. 2017, Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases.

Product Information

Test Quantum Blue® Infliximab Quantum Blue® Anti-Infliximab Quantum Blue® Adalimumab Quantum Blue® Anti-Adalimumab
Order Code LF-TLIF25/LF-TLIF10 LF-ADIF25/LF-ADIF10 LF-TLAD25/LF-TLAD10 LF-ADAD25/LF-ADAD10
Time to Result 15 min 15 min 15 min 15 min
Sample Type serum serum serum serum
Standard Range 0.4-20 µg/ml (180 µg/ml with dilution) Drug sensitive qualitative assay 1.3-35 µg/ml (500 µg/ml with dilution)  Drug sensitive qualitative assay
Reader Compatibility Quantum Blue® Reader 2nd Generation /

Quantum Blue® Reader 3rd Generation

Quantum Blue® Reader 2nd Generation /

Quantum Blue® Reader 3rd Generation

Quantum Blue® Reader 2nd Generation /

Quantum Blue® Reader 3rd Generation

Quantum Blue® Reader 2nd Generation /

Quantum Blue® Reader 3rd Generation

 

YouTube

By loading the video, you agree to YouTube's privacy policy.
Learn more

Load video

 

Downloads